ACPE Number: 0217-9999-20-179-H01-P
Pre-Sale Date: 09/16/2020
Content Release Date: 10/14/2020
Expiration Date: 10/12/2021
Activity Type: Application-based
CE Credits: 1.5 hours (BPS and ACPE)
Activity Fee: $99 (ASHP member); $159 (non-member)
Accreditation for Pharmacists
The American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The target audience for Oncology Guideline, Drug, and Publication Update 2020 is the pharmacist interested in learning more about the most critical guidelines that have been released in 2020 or for Board-certified Oncology Pharmacists (BCOPs) looking to earn recertification credit.
This course is intended for BCOPs in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS) to provide an overview of recent standards and guidelines that specialists should be familiar with in practice.
This online activity is approved for 1.5 hours of continuing pharmacy education credit and/or recertification credit.
Board certified pharmacists are eligible to receive up to 1.5 hours of recertification credit for completing this webinar. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.
This webinar is not intended for those preparing to take the BPS Oncology Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here:http://elearning.ashp.org/catalog/onc-review.
These activities are part of the ACCP and ASHP professional development program for BCOP recertification approved by the BPS.
For full program information, please visit: http://elearning.ashp.org/catalog/onc-recert
Oncology Guideline, Drug, and Publication Update 2020 (Cert #L209324)
After participating in this CPE activity, learners should be able to:
- Review newly approved oncologic agents and treatment regimens for patients with solid tumors.
- Evaluate literature associated with new approvals.
- Describe changes to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for various solid tumor diagnoses.
- Discuss incorporation of updates into clinical practice.
- Identify FDA-approvals of novel and existing therapies in the treatment of acute leukemias and myelodysplastic syndromes, chronic leukemias, lymphoma, and multiple myeloma.
- Evaluate clinical data supporting recent FDA-approvals in hematologic malignancies.
- Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current guidelines for patients with hematologic malignancies as it relates to newly approved therapies.
Planners, Presenters, and Reviewers
University of North Carolina Medical Center
Assistant Professor of Clinical Education
UNC Eshelman School of Pharmacy
Chapel Hill, North Carolina
Vanderbilt University Medical Center
Christine Walko, Pharm.D., BCOP
Theresa Mays, Pharm.D., BCOP
Vickie Bridges, Pharm.D., BCOP
Robert Cade, Pharm.D., BCOP
Chelsea Gustafson, Pharm.D., BCOP
Minhee Kang, Pharm.D., BCOP, BCPS
Sherri McCurry, Pharm.D., BCOP
Jennifer Ng, Pharm.D., BCOP, BCACP
Allison Novara, Pharm.D., BCOP
Danielle Schlafer, Pharm.D., BCOP
Arpita Shah, Pharm.D., BCOP
Alison Stauder, Pharm.D., BCOP
Stephanie Willenbring, Pharm.D., M.P.H., BCOP
Poppy Wilson, Pharm.D., BCOP
Susan Wojcicki, Pharm.D., BCOP
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.
All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP and required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identify and resolve conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.
All planners, presenters, and reviewers of this session report no financial relationships relevant to this activity.
Methods and CE Requirements
This activity consists of audio and slides, a PDF book chapter, an attestation statement, and an activity evaluation. Learners must review all content and complete the attestation statement and evaluation to receive continuing pharmacy education credit for the activity.
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
System Technical Requirements
Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.
View the minimum technical and system requirements for learning activities.
These activities were developed by ACCP and ASHP.